Medical/Pharmaceuticals
Skyline Therapeutics to Present at the ASGCT 26th Annual Meeting
SHANGHAI, May 3, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy...
2023-05-03 12:00
2857
China Jo-Jo Drugstores Receives Hangzhou Municipal People's Government Quality Management Excellence Award
HANGZHOU, China, May 2, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that the Co...
2023-05-02 20:30
4319
Meihua International Medical Technologies Co., Ltd.'s Subsidiary Completes Purchase of Land Use Right of Nearly 50,000 Square Meters in Hainan Free Trade Port Boao Hope City for the Construction of Integrated Medical Industrial Park
YANGZHOU, China, May 1, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the Company, via ...
2023-05-01 20:30
4699
I-MAB Filed 2022 Annual Report on Form 20-F
GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has filed its annual report on Form 20...
2023-05-01 20:00
3061
OBiO and CHINAGENE reached a strategic agreement of commercial manufacturing services for gene therapy products
SHANGHAI, April 29, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology ( Shanghai) Corp., Ltd. (OBiO) announced a strategic agreement of commercial manufacturing collaboration with CHINAGENE. Under the agreement, OBiO will provide holistic contract development and manufacturing services to CH...
2023-04-29 23:20
5302
ISS Collaboration - Singleron Biotechnologies GmbH joined the pursuit of "Reaching for the Stars"
MSIDA, Malta, April 28, 2023 /PRNewswire/ -- Yesterday, the celebrations for the MALETH project took place with a special keynote presentation from Dr.James Green, NASA's Former Chief Scientist. From Singleron, Dr. Samuel Kerr joined to present the yeast research studies aboard the International ...
2023-04-28 20:56
2920
HanAll Biopharma Reports First Quarter Results and Provides Business Update
* Financial results for the first quarter ended with revenue of KRW 28.8 billion, up by 20 percent compared to the same period in 2022 * HanAll made a strong start to 2023 with positive Phase 3 study results of anti-FcRn asset batoclimab for the treatment of generalized myasthenia gravis in C...
2023-04-28 19:00
3944
IMG-004 demonstrated extended half-life and durable pharmacodynamic characteristics in a Phase 1 study
SAN DIEGO, SHANGHAI and SYDNEY, April 28, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") today announced positive topline results from a Phase 1 study evaluating IMG-004 in healthy participants. IMG-004 is a potent, non-covalent, reversible, and brain permeable third-generation Br...
2023-04-28 17:00
2421
United Imaging Healthcare delivers its first annual report since going public, with revenue growth of nearly 30% in 2022
Along with the publication of its 2022 annual report and its first quarter report for 2023, United Imaging Healthcare released its ESG report today. SHANGHAI, April 28, 2023 /PRNewswire/ -- United Imaging Healthcare achieved a YoY revenue growth of 27.36 %, a figure published in the company's 202...
2023-04-28 15:53
2474
WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability
* The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10% reduction of waste intensity by 2027 compared with 2022. * The Company makes remarkable progress on environmental goals, achieving its water consumption intensity-reduction target in 2022, well a...
2023-04-28 14:43
3949
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio
- Exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio, the biotech investment firm - Targeting the KRW 146 trillion global autoimmune disease market with partner who has top global drug development expertis...
2023-04-28 08:58
3288
Ubie signs a broad collaboration agreement with Takeda Pharmaceuticals to promote digital transformation
- Aims to guide patients with rare and gastrointestinal diseases to appropriate medical care 〜Ubie will build on its achievements in the early detection of HAE and expand its collaboration with Takeda Pharmaceuticals to benefit patients in broader disease areas〜 NEW YORK, April 27, 2023 /PRNews...
2023-04-27 23:00
2628
Healint announces a collaboration with Saitama Medical University Hospital, Japan, to verify AI diagnosis of Migraine
PALO ALTO, Calif., April 27, 2023 /PRNewswire/ -- Saitama Medical University Hospital and Healint launched one of the world's first clinical studies titled "Verification of Headache AI diagnosis by using Electronic Headache Diary in Telemedicine". About 20 renowned headache specialists partici...
2023-04-27 21:15
3071
Yuyu Pharma, Dry Eye Pipeline Mechanism of Action and Pre-clinical Results Published
SEOUL, South Korea, April 27, 2023 /PRNewswire/ -- At ARVO 2023, Yuyu Pharma unveiled the results of its mechanism of action and head-to- head studies for its dry eye treatment peptide (project name: YP-P10). ARVO is the world's largest ophthalmic society and held its annual meeting inNew Orleans...
2023-04-27 21:00
5291
ASCO 2023 | Ascentage Pharma to Present Results from 4 Studies Highlighting Extended Therapeutic Potential of Lead Drug Candidates
SUZHOU, China, and ROCKVILLE, MD, April 27, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that results from four clinical studies of the c...
2023-04-27 17:44
2570
Dizal's Rapidly Evolving Oncology Pipeline to Make Waves at 2023 ASCO Meeting
Topline Results from Pivotal Studies of Sunvozertinib and Golidocitinib Selected for Oral Presentations SHANGHAI, April 26, 2023 /PRNewswire/ -- Dizal today announced that multiple clinical data of its two leading assets – sunvozertinib and golidocitinib have been selected for presentations...
2023-04-27 07:20
2848
Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative
SHANGHAI, April 26, 2023 /PRNewswire/ -- On April 25, 2023, World Health Organization (WHO) gave as the theme for World Malaria Day 2023 Time to deliver zero malaria: invest, innovate, implement. Within this theme, WHO will mainly focus on the third "i" – implement – and notably the critical imp...
2023-04-26 22:32
5000
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...
2023-04-26 22:15
4149
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of ul...
2023-04-26 21:16
3790
J INTS BIO, AACR 2023 - Presentation of preclinical study results of 'JIN-A04', an oral target therapy for HER2 exon insertion mutation NSCLC
SEOUL, South Korea, April 25, 2023 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered TKI 'JIN-A04' targeting NSCLC with HER2 exon 20 insertion mutation at the annual meeting of the American Association of Cancer Research 2023, which was held inOrlando,...
2023-04-26 09:53
2233
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 280 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
22100
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
12462
MAYPHARM Unveils HYALMASS AQUATOX, a Next-Generation Multi-Active Skin Solution for the Global Aesthetic Market
2026-09-26 08:55
9704
